scholarly journals Diagnosis and clinical management of enzymopathies

Hematology ◽  
2021 ◽  
Vol 2021 (1) ◽  
pp. 341-352
Author(s):  
Lucio Luzzatto

Abstract At least 16 genetically determined conditions qualify as red blood cell enzymopathies. They range in frequency from ultrarare to rare, with the exception of glucose-6-phosphate dehydrogenase deficiency, which is very common. Nearly all these enzymopathies manifest as chronic hemolytic anemias, with an onset often in the neonatal period. The diagnosis can be quite easy, such as when a child presents with dark urine after eating fava beans, or it can be quite difficult, such as when an adult presents with mild anemia and gallstones. In general, 4 steps are recommended: (1) recognizing chronic hemolytic anemia; (2) excluding acquired causes; (3) excluding hemoglobinopathies and membranopathies; (4) pinpointing which red blood cell enzyme is deficient. Step 4 requires 1 or many enzyme assays; alternatively, DNA testing against an appropriate gene panel can combine steps 3 and 4. Most patients with a red blood cell enzymopathy can be managed by good supportive care, including blood transfusion, iron chelation when necessary, and splenectomy in selected cases; however, some patients have serious extraerythrocytic manifestations that are difficult to manage. In the absence of these, red blood cell enzymopathies are in principle amenable to hematopoietic stem cell transplantation and gene therapy/gene editing.

1970 ◽  
Vol 23 (3) ◽  
pp. 617 ◽  
Author(s):  
BJ Richardson ◽  
AB Czuppon

The levels of six glycolytic enzymes were studied in three different populations of M. robU8tU8. Significant interpopulation differences were found for five of the enzymes. Glucose-6-phosphate dehydrogenase levels are up to three times higher than those found in eutherians. Keto-I-phospha.te aldolase substrate specificity differs radically from that found in eutherians. The enzymes studied are independently regulated.


1988 ◽  
Vol 10 (4) ◽  
pp. 409-416
Author(s):  
J.C. ARDERN ◽  
NORMA EDWARDS ◽  
K. HYDE ◽  
CARMEN JARDINE-WILKINSON ◽  
KORNELIA I. CINKOTAI ◽  
...  

1981 ◽  
Vol 27 (6) ◽  
pp. 541-545
Author(s):  
Kenji Taki ◽  
Koji Murakami ◽  
Takae Kawamura ◽  
Mieko Takamura ◽  
Reiji Wakusawa

2021 ◽  
Vol 12 ◽  
Author(s):  
Timothy J. McMahon ◽  
Cole C. Darrow ◽  
Brooke A. Hoehn ◽  
Hongmei Zhu

Metabolic homeostasis in animals depends critically on evolved mechanisms by which red blood cell (RBC) hemoglobin (Hb) senses oxygen (O2) need and responds accordingly. The entwined regulation of ATP production and antioxidant systems within the RBC also exploits Hb-based O2-sensitivity to respond to various physiologic and pathophysiologic stresses. O2 offloading, for example, promotes glycolysis in order to generate both 2,3-DPG (a negative allosteric effector of Hb O2 binding) and ATP. Alternatively, generation of the nicotinamide adenine dinucleotide phosphate (NADPH) critical for reducing systems is favored under the oxidizing conditions of O2 abundance. Dynamic control of ATP not only ensures the functional activity of ion pumps and cellular flexibility, but also contributes to the availability of vasoregulatory ATP that can be exported when necessary, for example in hypoxia or upon RBC deformation in microvessels. RBC ATP export in response to hypoxia or deformation dilates blood vessels in order to promote efficient O2 delivery. The ability of RBCs to adapt to the metabolic environment via differential control of these metabolites is impaired in the face of enzymopathies [pyruvate kinase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency], blood banking, diabetes mellitus, COVID-19 or sepsis, and sickle cell disease. The emerging availability of therapies capable of augmenting RBC ATP, including newly established uses of allosteric effectors and metabolite-specific additive solutions for RBC transfusates, raises the prospect of clinical interventions to optimize or correct RBC function via these metabolite delivery mechanisms.


Hypertension ◽  
1985 ◽  
Vol 7 (3_Pt_1) ◽  
pp. 319-325
Author(s):  
G. Bianchi ◽  
P. Ferrari ◽  
D. Trizio ◽  
M. Ferrandi ◽  
L. Torielli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document